

Invitation to Conference Call regarding Promore Pharma's Interim Report for the Third Quarter 2020

STOCKHOLM, 20 November 2020 – Promore Pharma AB (publ) publishes its interim report for the third quarter 2020 on 24 November 2020.

The next day, 25 November, the company will host a webcast telephone conference at 10.00 CET, with President and CEO Jonas Ekblom and CFO Erik Magnusson, where an update for the quarter and the recently released HEAL study will be provided. After the presentation there will be a Q&A session. The conference call will be held in English and can be accessed via computer, tablet, or telephone.

The number of attendees is limited, please register for the conference in advance on the following link:

<https://attendee.gotowebinar.com/register/421150747623991564>

The conference call will be recorded and made available on the company's website after the call, and on Västra Hamnen Corporate Finance Youtube channel.

For additional information, please contact

Jonas Ekblom, VD

Tel: [+46] 736 777 540

E-mail: jonas.ekblom@promorepharma.com

Erik Magnusson, CFO

Tel: [+46] 708 56 52 45

E-mail: erik.magnusson@promorepharma.com

Promore Pharma's Certified Adviser is Redeye AB.

Phone: [+46] 8 121 576 90

E-mail: certifiedadviser@redeye.se

Promore Pharma in brief

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications where very few efficacious prescription pharmaceuticals are available, thus, addressing high unmet medical needs. Promore Pharma's two projects are in late stage clinical development phase and have a very strong safety profile since they are based on innate substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical adhesions and scars, is being prepared for clinical phase III-studies in patients undergoing tendon repair surgery in the hand. Ropocamptide (LL-37) has recently finalized a clinical phase IIb study in patients with venous leg ulcers (VLU). The product candidates can also be deployed for other indications, such as preventing dermal scarring, adhesions after other surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market

For additional information, please contact

Jonas Ekblom, CEO

Phone: [+46] 736 777 540

E-mail: jonas.ekblom@promorepharma.com

Erik Magnusson, CFO

Phone: [+46] 708 565 245

E-mail: erik.magnusson@promorepharma.com

Promore Pharma's Certified Adviser is Redeye AB.

Phone: [+46] 8 121 576 90

E-mail: certifiedadviser@redeye.se

Promore Pharma in brief

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications where very few efficacious prescription pharmaceuticals are available, thus, addressing high unmet medical needs.

Promore Pharma's two projects are in late stage clinical development phase and have a very strong safety profile since they are based on innate substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical adhesions and scars, is being prepared for clinical phase III-studies in patients undergoing tendon repair surgery in the hand. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study in patients with venous leg ulcers (VLU). The product candidates can also be deployed for other indications, such as preventing dermal scarring, adhesions after other surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.

Attachments

[Invitation to Conference Call regarding Promore Pharma's Interim Report for the Third Quarter 2020](#)